U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H11N3O4.ClH
Molecular Weight 261.662
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ANCITABINE HYDROCHLORIDE

SMILES

Cl.[H][C@@]12OC3=NC(=N)C=CN3[C@]1([H])O[C@H](CO)[C@H]2O

InChI

InChIKey=KZOWNALBTMILAP-JBMRGDGGSA-N
InChI=1S/C9H11N3O4.ClH/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8;/h1-2,4,6-8,10,13-14H,3H2;1H/t4-,6-,7+,8-;/m1./s1

HIDE SMILES / InChI

Description

Cyclocytidine (also known as Ancitabine) is the prodrug of cytarabine, which is structurally similar to human deoxycytidine to be incorporated into human DNA and then kills the cell. Cyclocytidine was introduced as an antineoplastic agent for the treatment of lymphatic leukemia, sinus acceleration and an increase in systemic blood pressure. Cyclocytidine in combination with amsacrine were effective retrieval therapy for pediatric patients with acute nonlymphoblastic leukemia who were in relapse or unresponsive to frontline therapy.

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
acute nonlymphoblastic leukemia: Induction therapy consisted of intravenous (IV) Amsacrine (75 mg/m2) from days 1 to 5 and subcutaneous cyclocytidine (600 mg/m2) from days 1 to 7.
Route of Administration: Other
In Vitro Use Guide
Unknown